Trump Claims Drug Prices Cut 400-700%, Accused of Political Exaggeration

Summary

Donald Trump claimed he is reducing drug prices by 400% to 700%, a figure widely criticized as mathematically impossible ‘political hyperbole’ [Zhitong][]. During an event regarding an agreement with Regeneron, Trump admitted to ‘bragging’ and later adjusted his figures to 50-90% using what he called a ‘different calculation’ [][]. Analysts note that while he claims cuts, his administration’s import tariffs are actually driving up medication costs for consumers [][].

Impact Analysis

So Trump is back to his classic ‘hyperbolic’ playbook, claiming 400-700% drug price cuts. Mathematically, it’s nonsense—you can’t cut a price by more than 100% unless you’re paying people to take the meds [][]. He’s already walking it back to 50-90%, calling it ‘different math’ [].

The real signal here isn’t a systemic collapse in pharma margins, but a targeted PR campaign. He’s using a deal with Regeneron as a trophy to signal populist wins []. Meanwhile, the actual cost structure for the industry is worsening due to his own import tariffs, which are driving prices up for seniors [].

Bottom line: Don’t trade the ‘700%’ headline—it’s noise. The real risk for the sector isn’t these phantom price cuts; it’s the inflationary pressure from tariffs and the potential for erratic, company-specific ‘shakedowns’ for political optics. I’d stay cautious on names with high import exposure, but don’t buy the narrative that Big Pharma’s pricing power is being dismantled by these claims.